Mirum Pharmaceuticals

NASDAQ: MIRM ↗$123.00 USD~$2B MCAP

#Rare liver diseases #Cholestatic pruritus #Progressive familial intrahepatic cholestasis (PFIC)#Alagille syndrome #Primary biliary cholangitis (PBC)#Primary sclerosing cholangitis (PSC)#Chronic hepatitis B/D

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for rare liver diseases, with marketed products LIVMARLI and CHOLBAM.

Company Info

Sector:Small Molecule Pharma

Headquarters:Foster City, California, USA

Founded:2018

Website:mirumpharma.com/

Upcoming Milestones & Key Dates

2026 H2

Clinical readout

Phase 2b/3 volixibat interim analysis in PBC

2027 H1

Clinical readout

Phase 3 BOLD study readout for brelovitug in chronic hepatitis D

Clinical Development Pipeline

LIVMARLI (maralixibat)

Target: IBAT (ileal bile acid transporter)

Cholestatic pruritus in PFIC, Alagille syndrome

Preclinical

Phase 1

Phase 2

Phase 3

Approved

CHOLBAM (cholic acid)

Target: Bile acid replacement

Bile acid synthesis disorders

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Volixibat

Target: IBAT

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Mirum, Incyte bolster case for approval in rare bone disease despite mid-stage miss ↗

Mirum Pharmaceuticals and Incyte are pushing forward with regulatory submissions for their rare bone disease therapies despite mid-stage trial misses, citing subgroup and biomarker data to support approval.

Leadership Team

Chris Peetz

Co-Founder & CEO

Mike Grey

Executive Chairman

Ajay Narasimha

SVP Corporate Strategy & Business Development

Careers & Job Openings

See all open roles

Multiple Departments

Foster City, CA + Remote

Apply Now →